Ardea's Oral MEK Inhibitor Shows Favorable Anti-Tumor Activity
Posted on: Friday, 26 October 2007, 06:00 CDT
Ardea Biosciences has reported positive preclinical data on its lead MEK inhibitor, which suggests it has favorable properties, including oral dosing, excellent selectivity and low central nervous system penetration.
In mouse xenograft studies, when MEK inhibitor (RDEA119) was dosed orally once daily for 14 days, it caused significant inhibition and delay of tumor growth. Inhibition of pERK in tumors (the target of therapy) are observed at significantly lower concentrations compared to those required to inhibit brain. This very limited brain penetration suggests the potential for reduced central nervous system side effects, according to the company.
Defects in the RAS/RAF/MEK/ERK signaling pathway are closely associated with the development of human tumors, such as melanoma, colon, lung and thyroid cancers. RDEA119, the lead compound from Ardea's MEK inhibitor program, is a potent, non-ATP competitive, highly-selective inhibitor of mitogen-activated ERK kinase (MEK).
Barry Quart, president and CEO of Ardea Biosciences, said: "We currently plan to initiate a Phase I study of RDEA119 in patients with advanced cancer this quarter and plan to evaluate RDEA119 for inflammatory diseases next year."
Source: Datamonitor
Related Articles
- Ardea Biosciences Presents Preclinical Data on Its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy With Other Anti-Cancer Agents in Multiple Tumor Types
- Ardea Biosciences Initiates a Phase 1/2 Study of RDEA119, Its Lead MEK Inhibitor, in Combination With Nexavar(R) (Sorafenib) in Patients With Advanced Cancer
- Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on Its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
- Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
- Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
- Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
- New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
- Preclinical Data on Lead MEK Inhibitor, RDEA119, to Be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
 |
 |
User Comments (0)
RSS Feeds